Αποτελέσματα Αναζήτησης
25 Μαΐ 2023 · The following examples show overall survival rates for people with different types of cancer, along with the percentage of those receiving chemotherapy as part of their treatment.
23 Ιουν 2022 · Testicular cancer survival has increased from 83% in patients who were diagnosed during the mid-1970s to 95% in the most recent time period, largely because of the success of chemotherapy regimens for advanced disease.
11 Ιουν 2019 · The majority of thyroid cancer survivors are women (78%), reflecting that the incidence in women is more than double that in men. 1 The median age at diagnosis—55 years for males and 50 years for females—is younger than that for most other adult cancers. 7
Nearly two-thirds (64%) of survivors are 65 years of age or older, while only 1 in 10 are younger than 50 years of age (Table 2), with considerable variation by cancer type (Figure 2). Table 1. Estimated Number of US Cancer Survivors by Sex and Years Since Diagnosis as of January 1, 2019. Male and Female.
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
Our results suggest neoadjuvant pertuzumab based regimens confer superior pCR rates with similar tolerability compared to AC-TH. The observed pCR rates align with results observed in TRYPHAENA. In TRYPHAENA, the pCR rate for FEC-THP was 54.7%, while we observed a pCR rate of 60% for dose-dense AC-THP.
23 Νοε 2021 · Based on the propensity matched cohorts of 879 chemotherapy-exposed vs 1611 chemotherapy-naïve patients, overall survival rates at 18 and 30 months were 76.3 vs 70.5% and 61.6 vs 56.0%, favoring chemotherapy-exposed patients (Figure 1B).
